



Clinical trial results:

CONVINCE - (COLchicine for prevention of Vascular Inflammation in Non- CardioEmbolic stroke) – a randomised clinical trial of low-dose colchicine for secondary prevention after stroke

Summary

EudraCT number	2015-004505-16
Trial protocol	IE ES GB DE CZ DK PT BE LT NL
Global end of trial date	31 January 2024

Results information

Result version number	v1 (current)
This version publication date	07 June 2025
First version publication date	07 June 2025
Summary attachment (see zip file)	The Lancet CONVINCE June 2024 (The Lancet CONVINCE main report_2024.pdf)

Trial information

Trial identification

Sponsor protocol code	CONVINCE
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02898610
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	University College Dublin
Sponsor organisation address	UCD Clinical Research Centre, Dublin, Ireland, D07 A8NN
Public contact	Prof Peter Kelly, The Irish Stroke Clinical Trials Network, 353 17164576, pjkelly@mater.ie
Scientific contact	Prof Peter Kelly, The Irish Stroke Clinical Trials Network, 353 17164575, pjkelly@mater.ie

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 January 2024
Is this the analysis of the primary completion data?	Yes
Primary completion date	31 January 2024
Global end of trial reached?	Yes
Global end of trial date	31 January 2024
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To investigate the efficacy of low dose colchicine (0.5mg/day) plus usual care (antiplatelet, lipid-lowering, antihypertensive treatment, and appropriate lifestyle advice) compared with usual care alone to prevent non-fatal recurrent ischaemic stroke, myocardial infarction, cardiac arrest, and vascular death after ischaemic stroke or transient ischaemic attack (TIA) not caused by cardiac embolism or other defined causes unrelated to atherosclerosis.

Protection of trial subjects:

PROBE Study design aligned with clinical care.

Patient visits every 6 months.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	12 December 2016
Long term follow-up planned	Yes
Long term follow-up rationale	Safety, Efficacy, Ethical reason, Regulatory reason, Scientific research
Long term follow-up duration	3 Years
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Netherlands: 18
Country: Number of subjects enrolled	Poland: 68
Country: Number of subjects enrolled	Portugal: 122
Country: Number of subjects enrolled	Spain: 277
Country: Number of subjects enrolled	United Kingdom: 1219
Country: Number of subjects enrolled	Belgium: 365
Country: Number of subjects enrolled	Czechia: 21
Country: Number of subjects enrolled	Denmark: 74
Country: Number of subjects enrolled	Estonia: 12
Country: Number of subjects enrolled	Germany: 428
Country: Number of subjects enrolled	Ireland: 478
Country: Number of subjects enrolled	Lithuania: 14
Country: Number of subjects enrolled	Canada: 36
Country: Number of subjects enrolled	Switzerland: 22
Worldwide total number of subjects	3154
EEA total number of subjects	1877

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	1367
From 65 to 84 years	1707
85 years and over	80

Subject disposition

Recruitment

Recruitment details:

A randomised, parallel-group, open-label, blinded endpoint assessed trial comparing long-term colchicine (0.5 mg orally per day) plus guideline-based usual care with usual care only. Hospital-based patients with non-severe, non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack were eligible.

Pre-assignment

Screening details:

Hospital-based patients with non-severe, non-cardioembolic ischaemic stroke or high-risk transient ischaemic attack were eligible.

Full inclusion / exclusion outlined in the trial protocol.

Period 1

Period 1 title	Overall Trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Single blind
Roles blinded	Assessor ^[1]

Blinding implementation details:

Only outcome assessors were blinded to which arm the patient was randomised to.

Arms

Are arms mutually exclusive?	Yes
------------------------------	-----

Arm title	Intervention Arm
------------------	------------------

Arm description:

Low-dose colchicine, plus usual care (defined in the protocol)

Arm type	Experimental
Investigational medicinal product name	Colchicine
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Low-dose colchicine, 0.5mg/day, oral administration

Arm title	Control Arm
------------------	-------------

Arm description:

Usual care only, defined as anti-platelet, lipid-lowering, and anti-hypertensive treatment and lifestyle advice (smoking cessation, diet and physical activity), as deemed appropriate by the treating clinician.

Arm type	No intervention
----------	-----------------

No investigational medicinal product assigned in this arm

Notes:

[1] - The roles blinded appear inconsistent with a simple blinded trial.

Justification: Outcome assessor was blinded

Number of subjects in period 1 ^[2]	Intervention Arm	Control Arm
Started	1569	1575
Completed	1565	1572
Not completed	4	3
Protocol deviation	4	3

Notes:

[2] - The number of subjects reported to be in the baseline period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 10 patients withdrew consent hence the difference in numbers

Number of patients enrolled 3154.

Ten patients withdrew consent for analysis of their data, leaving 3144 patients in the intention-to-treat analysis: 1569 (colchicine and usual care) and 1575 (usual care alone).

Baseline characteristics

Reporting groups

Reporting group title	Intervention Arm
Reporting group description:	
Low-dose colchicine, plus usual care (defined in the protocol)	
Reporting group title	Control Arm
Reporting group description:	
Usual care only, defined as anti-platelet, lipid-lowering, and anti- hypertensive treatment and lifestyle advice (smoking cessation, diet and physical activity), as deemed appropriate by the treating clinician.	

Reporting group values	Intervention Arm	Control Arm	Total
Number of subjects	1569	1575	3144
Age categorical			
Age 40 years or greater			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	0	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age 40 and greater	1569	1575	3144
Gender categorical			
Units: Subjects			
Female	488	465	953
Male	1081	1110	2191

End points

End points reporting groups

Reporting group title	Intervention Arm
Reporting group description: Low-dose colchicine, plus usual care (defined in the protocol)	
Reporting group title	Control Arm
Reporting group description: Usual care only, defined as anti-platelet, lipid-lowering, and anti- hypertensive treatment and lifestyle advice (smoking cessation, diet and physical activity), as deemed appropriate by the treating clinician.	

Primary: Outcomes reported

End point title	Outcomes reported
End point description: Primary efficacy analysis was by intention to treat, comparing time to primary outcome event in colchicine-treated and usual-care groups via a log-rank test. Events confirmed through centralised adjudication to meet protocol-defined primary outcome criteria, were included in the analyses of the number of occurrences of the composite primary outcome for the respective treatment group. The components of the primary composite efficacy outcome measure are defined below: Non-fatal ischaemic stroke (defined in Protocol) Non-fatal myocardial infarction Non-fatal cardiac arrest Hospitalization for Unstable Angina: TIMI definition Vascular death	
End point type	Primary
End point timeframe: The primary efficacy outcome measure will be time to the first occurrence of non-fatal recurrent ischaemic stroke, non-fatal myocardial infarction, non-fatal cardiac arrest, hospitalization for unstable angina or vascular death.	

End point values	Intervention Arm	Control Arm		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1569	1575		
Units: number of outcomes	153	185		

Statistical analyses

Statistical analysis title	Primary Analysis
Statistical analysis description: The statistical approach was a comparison of time to primary outcome event (first recurrent event in the	

outcome composite) in colchicine-treated and usual-care groups.

The effect size and precision was reported as hazard ratio with 95% confidence intervals using Cox proportional hazards modelling. The hazard ratio was adjusted for the three mandatory minimisation variables (age, duration since last event, type of qualifying event) specified in the randomisation algorithm.

Comparison groups	Intervention Arm v Control Arm
Number of subjects included in analysis	3144
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	≤ 0.048 ^[1]
Method	COX PH Model
Parameter estimate	Hazard ratio (HR)
Confidence interval	
level	95 %

Notes:

[1] - For the primary analysis, a P-value of 0.048 or less will be considered as statistically significant (two-sided alpha), accounting for the 'alpha-spend' of 0.001 in each of 2 interim analysis.

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Adverse event collection began at randomisation and finished at the end-of-trial assessment (28 days after last dose of study medication).

Adverse event reporting additional description:

Subjects were interviewed during each subject visit to determine if an adverse event had occurred. Specific monitoring for the following adverse events performed in colchicine-treated and usual care groups:

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
Dictionary version	26.1

Reporting groups

Reporting group title	Intervention Arm
-----------------------	------------------

Reporting group description:

Low-dose colchicine, plus usual care (defined in the protocol)

Reporting group title	Control Arm
-----------------------	-------------

Reporting group description:

Usual care only, defined as anti-platelet, lipid-lowering, and anti- hypertensive treatment and lifestyle advice (smoking cessation, diet and physical activity), as deemed appropriate by the treating clinician.

Serious adverse events	Intervention Arm	Control Arm	
Total subjects affected by serious adverse events			
subjects affected / exposed	594 / 1569 (37.86%)	596 / 1575 (37.84%)	
number of deaths (all causes)	69	70	
number of deaths resulting from adverse events	53	53	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
subjects affected / exposed	73 / 1569 (4.65%)	73 / 1575 (4.63%)	
occurrences causally related to treatment / all	0 / 87	0 / 81	
deaths causally related to treatment / all	0 / 21	0 / 26	
Vascular disorders			
Vascular disorders			
subjects affected / exposed	43 / 1569 (2.74%)	33 / 1575 (2.10%)	
occurrences causally related to treatment / all	0 / 48	0 / 35	
deaths causally related to treatment / all	0 / 6	0 / 4	
Surgical and medical procedures			

Surgical and medical procedures subjects affected / exposed	91 / 1569 (5.80%)	101 / 1575 (6.41%)	
occurrences causally related to treatment / all	0 / 110	0 / 114	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
General disorders and administration site conditions			
subjects affected / exposed	25 / 1569 (1.59%)	19 / 1575 (1.21%)	
occurrences causally related to treatment / all	0 / 26	0 / 19	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			
Immune System Disorders			
subjects affected / exposed	3 / 1569 (0.19%)	0 / 1575 (0.00%)	
occurrences causally related to treatment / all	0 / 4	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Social circumstances			
Social circumstances			
subjects affected / exposed	1 / 1569 (0.06%)	0 / 1575 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Reproductive system and breast disorders			
Reproductive system and breast disorders			
subjects affected / exposed	4 / 1569 (0.25%)	4 / 1575 (0.25%)	
occurrences causally related to treatment / all	0 / 4	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Respiratory, thoracic and mediastinal disorders			
subjects affected / exposed	31 / 1569 (1.98%)	38 / 1575 (2.41%)	
occurrences causally related to treatment / all	0 / 45	0 / 46	
deaths causally related to treatment / all	0 / 6	0 / 3	
Psychiatric disorders			
Psychiatric disorders			

subjects affected / exposed	14 / 1569 (0.89%)	16 / 1575 (1.02%)	
occurrences causally related to treatment / all	0 / 15	0 / 19	
deaths causally related to treatment / all	0 / 2	0 / 0	
Product issues			
Product issues			
subjects affected / exposed	1 / 1569 (0.06%)	0 / 1575 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Hepatobiliary disorders			
subjects affected / exposed	10 / 1569 (0.64%)	12 / 1575 (0.76%)	
occurrences causally related to treatment / all	0 / 13	0 / 13	
deaths causally related to treatment / all	0 / 0	0 / 1	
Investigations			
Investigations			
subjects affected / exposed	26 / 1569 (1.66%)	24 / 1575 (1.52%)	
occurrences causally related to treatment / all	0 / 28	0 / 25	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Injury, poisoning and procedural complications			
subjects affected / exposed	62 / 1569 (3.95%)	62 / 1575 (3.94%)	
occurrences causally related to treatment / all	0 / 71	0 / 69	
deaths causally related to treatment / all	0 / 0	0 / 0	
Congenital, familial and genetic disorders			
Congenital, familial and genetic disorders			
subjects affected / exposed	3 / 1569 (0.19%)	5 / 1575 (0.32%)	
occurrences causally related to treatment / all	0 / 3	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Cardiac disorders			
subjects affected / exposed	44 / 1569 (2.80%)	54 / 1575 (3.43%)	
occurrences causally related to treatment / all	0 / 59	0 / 69	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			

Nervous system disorders			
subjects affected / exposed	112 / 1569 (7.14%)	116 / 1575 (7.37%)	
occurrences causally related to treatment / all	0 / 135	0 / 149	
deaths causally related to treatment / all	0 / 1	0 / 1	
Blood and lymphatic system disorders			
Blood and lymphatic system disorders			
subjects affected / exposed	9 / 1569 (0.57%)	10 / 1575 (0.63%)	
occurrences causally related to treatment / all	0 / 10	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Ear and labyrinth disorders			
subjects affected / exposed	7 / 1569 (0.45%)	10 / 1575 (0.63%)	
occurrences causally related to treatment / all	0 / 7	0 / 11	
deaths causally related to treatment / all	0 / 0	0 / 0	
Eye disorders			
Eye Disorders			
subjects affected / exposed	4 / 1569 (0.25%)	7 / 1575 (0.44%)	
occurrences causally related to treatment / all	0 / 4	0 / 7	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Gastrointestinal disorders			
subjects affected / exposed	46 / 1569 (2.93%)	48 / 1575 (3.05%)	
occurrences causally related to treatment / all	0 / 57	0 / 48	
deaths causally related to treatment / all	0 / 0	0 / 1	
Skin and subcutaneous tissue disorders			
Skin and subcutaneous tissue disorders			
subjects affected / exposed	6 / 1569 (0.38%)	4 / 1575 (0.25%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Renal and urinary disorders			
subjects affected / exposed	23 / 1569 (1.47%)	16 / 1575 (1.02%)	
occurrences causally related to treatment / all	0 / 28	0 / 20	
deaths causally related to treatment / all	0 / 0	0 / 2	
Endocrine disorders			

Endocrine disorders			
subjects affected / exposed	1 / 1569 (0.06%)	1 / 1575 (0.06%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Musculoskeletal and connective tissue disorders			
Musculoskeletal and connective tissue disorders			
subjects affected / exposed	20 / 1569 (1.27%)	29 / 1575 (1.84%)	
occurrences causally related to treatment / all	0 / 20	0 / 33	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Infections and infestations			
subjects affected / exposed	256 / 1569 (16.32%)	252 / 1575 (16.00%)	
occurrences causally related to treatment / all	0 / 316	0 / 313	
deaths causally related to treatment / all	0 / 11	0 / 9	
Metabolism and nutrition disorders			
Metabolism and nutrition disorders			
subjects affected / exposed	18 / 1569 (1.15%)	20 / 1575 (1.27%)	
occurrences causally related to treatment / all	0 / 19	0 / 21	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Intervention Arm	Control Arm	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1013 / 1569 (64.56%)	925 / 1575 (58.73%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
subjects affected / exposed	44 / 1569 (2.80%)	40 / 1575 (2.54%)	
occurrences (all)	49	42	
Vascular disorders			
Vascular disorders			
subjects affected / exposed	111 / 1569 (7.07%)	100 / 1575 (6.35%)	
occurrences (all)	112	115	
Surgical and medical procedures			

Surgical and medical procedures subjects affected / exposed occurrences (all)	88 / 1569 (5.61%) 110	93 / 1575 (5.90%) 115	
General disorders and administration site conditions General disorders and administration site conditions subjects affected / exposed occurrences (all)	99 / 1569 (6.31%) 115	105 / 1575 (6.67%) 122	
Immune system disorders Immune system disorders subjects affected / exposed occurrences (all)	9 / 1569 (0.57%) 9	2 / 1575 (0.13%) 2	
Social circumstances Social circumstance subjects affected / exposed occurrences (all)	2 / 1569 (0.13%) 2	1 / 1575 (0.06%) 1	
Reproductive system and breast disorders Reproductive system and breast disorders subjects affected / exposed occurrences (all)	18 / 1569 (1.15%) 18	31 / 1575 (1.97%) 34	
Respiratory, thoracic and mediastinal disorders Respiratory, thoracic and mediastinal disorders subjects affected / exposed occurrences (all)	101 / 1569 (6.44%) 112	109 / 1575 (6.92%) 135	
Psychiatric disorders Psychiatric disorders subjects affected / exposed occurrences (all)	64 / 1569 (4.08%) 69	62 / 1575 (3.94%) 71	
Product issues Product issues subjects affected / exposed occurrences (all)	0 / 1569 (0.00%) 0	2 / 1575 (0.13%) 2	
Hepatobiliary disorders Hepatobiliary disorders subjects affected / exposed occurrences (all)	17 / 1569 (1.08%) 18	12 / 1575 (0.76%) 13	
Investigations			

Investigations subjects affected / exposed occurrences (all)	206 / 1569 (13.13%) 288	177 / 1575 (11.24%) 264	
Injury, poisoning and procedural complications Injury, poisoning and procedural complications subjects affected / exposed occurrences (all)	136 / 1569 (8.67%) 182	125 / 1575 (7.94%) 163	
Congenital, familial and genetic disorders Congenital, familial and genetic disorders subjects affected / exposed occurrences (all)	8 / 1569 (0.51%) 8	7 / 1575 (0.44%) 7	
Cardiac disorders Cardiac disorders subjects affected / exposed occurrences (all)	101 / 1569 (6.44%) 119	117 / 1575 (7.43%) 139	
Nervous system disorders Nervous System Disorders subjects affected / exposed occurrences (all)	253 / 1569 (16.12%) 338	264 / 1575 (16.76%) 346	
Blood and lymphatic system disorders Blood and lymphatic system disorders subjects affected / exposed occurrences (all)	31 / 1569 (1.98%) 34	40 / 1575 (2.54%) 55	
Ear and labyrinth disorders Ear and labyrinth disorders subjects affected / exposed occurrences (all)	29 / 1569 (1.85%) 32	30 / 1575 (1.90%) 32	
Eye disorders Eye disorders subjects affected / exposed occurrences (all)	59 / 1569 (3.76%) 66	49 / 1575 (3.11%) 54	
Gastrointestinal disorders Gastrointestinal disorders subjects affected / exposed occurrences (all)	296 / 1569 (18.87%) 409	131 / 1575 (8.32%) 172	

Skin and subcutaneous tissue disorders Skin and subcutaneous tissue disorders subjects affected / exposed occurrences (all)	99 / 1569 (6.31%) 115	55 / 1575 (3.49%) 64	
Renal and urinary disorders Renal and urinary disorders subjects affected / exposed occurrences (all)	80 / 1569 (5.10%) 88	75 / 1575 (4.76%) 90	
Endocrine disorders Endocrine disorders subjects affected / exposed occurrences (all)	4 / 1569 (0.25%) 5	14 / 1575 (0.89%) 16	
Musculoskeletal and connective tissue disorders Musculoskeletal and connective tissue disorders subjects affected / exposed occurrences (all)	200 / 1569 (12.75%) 261	198 / 1575 (12.57%) 267	
Infections and infestations Infections and infestations subjects affected / exposed occurrences (all)	226 / 1569 (14.40%) 316	240 / 1575 (15.24%) 319	
Metabolism and nutrition disorders Metabolism and nutrition disorders subjects affected / exposed occurrences (all)	94 / 1569 (5.99%) 109	110 / 1575 (6.98%) 127	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
20 March 2020	Temporary Halt to recruitment and contingency arrangements due to COVID 19 pandemic
15 May 2020	Recruitment recommenced
01 February 2021	Increase sample size Change in study timelines Modification of the trial procedures to reduce risk of COVID to trial participants from follow-up visits:

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
20 March 2020	Temporary pause in recruitment due to onset of COVID 19 pandemic	15 May 2020

Notes:

Limitations and caveats

None reported

Online references

<http://www.ncbi.nlm.nih.gov/pubmed/38857611>